The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
Open accessAbstract
Construction of a bispecific single-chain antibody derivative is described that consists of two different single-chain Fv fragments joined through a Gly-Ser linker. One specificity of the two Fv fragments is directed against the CD3 antigen of human T cells and the other is directed against the epithelial 17-1A antigen; the latter had been found in a clinical trial to be a suitable target for antibody therapy of minimal residual colorectal cancer. The construct could be expressed in CHO cells as a fully functional protein, while its periplasmic expression in Escherichia coli resulted in a nonfunctional protein only. The antigen-binding properties of the bispecific single-chain antibody are indistinguishable from those of the corresponding univalent single-chain Fv fragments. By redirecting human peripheral T lymphocytes against 17-1A-positive tumor cells, the bispecific antibody proved to be highly cytotoxic at nanomolar concentrations as demonstrated by 51Cr release assay on various cell lines. The described bispecific construct has a molecular mass of 60 kDa and can be easily purified by its C-terminal histidine tail on a Ni-NTA chromatography column. As bispecific antibodies have already been shown to be effective in vivo in experimental tumor systems as well as in phase-one clinical trials, the small CD3/17-1A-bispecific antibody may be more efficacious than intact antibodies against minimal residual cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This new kind of bsAb proved to be highly cytotoxic at nanomolar concentrations against various cell lines, using unstimulated human PBMCs in the absence of co-signaling. 44”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new method for predicting signal sequence cleavage sites
von HEIJNE, G. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.11.4683 · Cited by 4,473
Pelletier, J., & Sonenberg, N. (1988) · Nature · doi:10.1038/334320a0 · Cited by 1,953
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610
pEF-BOS, a powerful mammalian expression vector
Mizushima, S., & Nagata, S. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.17.5322 · Cited by 1,594
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 882
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
Orlandi, R., Güssow, D., Jones, P. T., & Winter, G. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3833 · Cited by 715
Riethmüller, G., Gruber, R., Schneider-Gädicke, E., Schlimok, G., Witte, J., Raab, R., Pichlmayr, R., Pichlmaier, H., Schmiegel, W., Buggisch, P., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92398-1 · Cited by 633
Self-citationHybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
A comparison of strategies to stabilize immunoglobulin Fv-fragments
Glockshuber, R., Malia, M., Pfitzinger, I., & Plückthun, A. (1990) · Biochemistry · doi:10.1021/bi00458a002 · Cited by 473
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M. (1985) · Nature · doi:10.1038/316354a0 · Cited by 337
Preliminary trial of specific targeting therapy against malignant glioma
Nitta, T., Yagita∥, H., Okumura, K., Sato, K., & Ishii, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90205-j · Cited by 235
Göitlinger, H. G., Funke, I., Johnson, J. P., Gokel, J. M., & Riethmüller, G. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380109 · Cited by 233
Self-citationA recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B., & Pastan, I. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7538 · Cited by 223
Formation of a bispecific antibody by the use of leucine zippers
Kostelny, S. A., Cole, M. S., & Tso, J. Y. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.5.1547 · Cited by 211
Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.
Staerz, U. D., & Bevan, M. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1453 · Cited by 208
The use of hybrid hybridomas to target human cytotoxic T lymphocytes
Lanzavecchia, A., & Scheidegger, D. (1987) · European Journal of Immunology · doi:10.1002/eji.1830170118 · Cited by 198
[42] Selection and coamplification of heterologous genes in mammalian cells
Kaufman, R. J. (1990) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(90)85044-o · Cited by 182
Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2.
Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewski, Z., Koprowski, H., & Linnenbach, A. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.9.3542 · Cited by 173
Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
Renner, C., Jung, W. E., Şahin, U., Denfeld, R. W., Pohl, C., Trümper, L. H. P., Hartmann, F., Diehl, V., van Lier, R. A. W., & Pfreundschuh, M. G. (1994) · Science · doi:10.1126/science.8171337 · Cited by 156
[34] Expression of functional antibody Fv and Fab fragments in Escherichia coli
Plückthun, A., & Skerra, A. (1989) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(89)78036-8 · Cited by 141
Construction, expression, and activity of a bivalent bispecific single-chain antibody.
Mallender, W. D., & Voss, E. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42334-9 · Cited by 120
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
Bolhuis, R. L. H., Lamers, C. H., Goey, S. H., Eggermont, A. M. M., Trimbos, J. B. M. Z., Stoter, G., Lanzavecchia, A., Re, E. D., Miotti, S., & Raspagliesi, F. (1992) · PubMed · Cited by 108
Gruber, M., Schodin, B. A., Wilson, E. R., & Kranz, D. M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.11.5368 · Cited by 98
Adhesion receptors in lymphocyte activation
Collins, T. L., Kassner, P. D., Bierer, B. E., & Burakoff, S. J. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90117-1 · Cited by 88
Titus, J. A., Garrido, M. A., Hecht, T. T., Winkler, D. F., Wunderlich, J. R., & Segal, D. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.11.4018 · Cited by 85
Mezzanzanica, D., Garrido, M. A., Neblock, D. S., Daddona, P. E., Andrew, S. M., Zurawski, V. R., Segal, D. M., & Wunderlich, J. R. (1991) · PubMed · Cited by 69
Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma
Weiner, G. J., & Hillstrom, J. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.4035 · Cited by 67
Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells.
Traunecker, A., Lanzavecchia, A., & Karjalainen, K. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04932.x · Cited by 67
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner, G. J., Kostelny, S. A., Hillstrom, J. R., Cole, M. S., Link, B. K., Wang, S. L., & Tso, J. Y. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.5.2385 · Cited by 64
Target cell‐induced T cell activation with bi‐ and trispecific antibody fragments
Jung, G., Freimann, U., von Marschall, Z., Reisfeld, R. A., & Wilmanns, W. (1991) · European Journal of Immunology · doi:10.1002/eji.1830211020 · Cited by 61
Treatment of mice bearing BCL1 lymphoma with bispecific antibodies
Brissinck, J., Demanet, C., Moser, M. A., Léo, O., & Thielemans, K. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.4019 · Cited by 56
Cell-mediated cytotoxic mechanisms
Squier, M. K. T., & Cohen, J. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90126-0 · Cited by 52
Targeted cytotoxic cells in human peripheral blood lymphocytes.
Garrido, M. A., Perez, P., Titus, J. A., Valdayo, M. J., Winkler, D. F., Barbieri, S. A., Wunderlich, J. R., & Segal, D. M. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.8.2891 · Cited by 49
Qian, J. H., Titus, J. A., Andrew, S. M., Mezzanzanica, D., Garrido, M. A., Wunderlich, J. R., & Segal, D. M. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3250 · Cited by 49
Tutt, A. N. J., Stevenson, G. T., & Glennie, M. J. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.1.60 · Cited by 44
Tibben, J. G., Boerman, O. C., Claessens, R. A. M. J., Corstens, F. H. M., van Deuren, M., Mulder, P., van der Meer, J. W. M., Keijser, K. G. G., & Massuger, L. F. A. G. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.1003 · Cited by 27
Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice.
Weiner, G. J. (1992) · PubMed · Cited by 9
Research works printed but not linked: 6
- [9]Staerz, U. D. & Bevan, M. J. (1986) Proc. Natl. Acad. Sci. USA 83, 1453–1457.
- [13]Hollinger, P., Prospero, T. & Winter, G. (1993) Proc. Natl. Acad. Sci. USA 90, 6444–6448.
- [16]Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M.-S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R. & Oppermann, H. (1988) Proc. Natl. Acad. Sci. USA 85, 5879–5883.
- [18]Orlandi, R., Güssow, D. H., Jones, P. T. & Winter, G. (1989) Proc. Natl. Acad. Sci. USA 86, 3833–3837.
- [25]Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewski, Z., Koprowsky, H. & Linnebach, A. J. (1990) Proc. Natl. Acad. Sci. USA 87, 3542–3564.
- [30]Brinkmann, U., Reiter, Y., Jung, S., Lee, B. & Pastan, I. (1993) Proc. Natl. Acad. Sci. USA 90, 7538–7542.
Cited by
Sorted by citations
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Self-citationThe making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 961
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914
Self-citationT cell-engaging therapies — BiTEs and beyond
Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 675
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711
Metadata
- Authors
- Mack, M., Riethmüller, G., & Kufer, P.
- Affiliations
- Institut für Immunologie (DE)
- ORCID
- Mack, M
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1995-07-18
- Volume
- 92
- Issue
- 15
- Pages
- 7021-7025
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC41463
- OpenAlex
- W2086146164
- Cited by
- 351
- References
- 39
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 15 · 2023: 7 · 2022: 10 · 2021: 20 · 2020: 12 · 2019: 22 · 2018: 19 · 2017: 20 · 2016: 12 · 2015: 22 · 2014: 16 · 2013: 13 · 2012: 14
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- bispecific antibodies, single-chain antibody, single-chain Fv fragments, CD3 antigen, colorectal cancer, minimal residual disease, tumor cell killing, CHO cell expression, Ni-NTA affinity purification, antibody therapy
- MeSH terms
- Amino Acid Sequence, Antibody Specificity, Antineoplastic Agents, Base Sequence, Cloning, Molecular, Escherichia coli, Immunoglobulin Fragments, Immunoglobulin Variable Region, Molecular Sequence Data, Recombinant Proteins, Tumor Cells, Cultured, Blotting, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
